Overview
Dr. Reddy’s Laboratories Ltd. is an India-headquartered pharmaceutical company that develops and supplies generic medicines, active pharmaceutical ingredients and pharmaceutical services, biosimilars, innovative medicines, and consumer-health products. Its principal business segments are Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others.[1]
The company serves markets worldwide, with Global Generics sales across North America, India, Europe, Russia, other former Soviet Union countries and Romania, and the rest of the world.[2] Its stated purpose is to accelerate access to affordable and innovative medicines.[3] Founded in 1984, Dr. Reddy’s reported FY2026 revenue of Rs 335.933 billion (US$3.580 billion) and 27,527 employees as of March 31, 2026.[4][5][6] [1][2][3][4][5][6][1][3][4]
Products & services
Dr. Reddy’s product portfolio includes generic medicines, active pharmaceutical ingredients (APIs), biosimilars, innovative medicines and consumer-health products. Named examples include Omez, Razo, Econorm and Redotil in gastrointestinal treatments; BixiBat (elobixibat) for chronic constipation; and Stugeron, an antivertigo brand. Its consumer-health and nicotine-replacement portfolios include Nicotinell, Nicabate, Thrive and Habitrol, offered in formats such as lozenges, patches and gum.[7][8][9][10]
Other products and programs include Sensimune, an immunotherapy for house-dust-mite-induced allergies, and Beyfortus (nirsevimab), which the company promotes and distributes in India with Sanofi for prevention of RSV disease in infants. HLX15, a partnered daratumumab biosimilar candidate, is in development rather than a marketed product. The company’s August 2026 finished-formulations catalogue details products by strength, dosage form, therapeutic category and development or filing status.[11][12][13]
Manufacturing and development capabilities cover oral solid medicines, injectables and other dosage forms, as well as API development and production. The company describes API capabilities spanning steroids, peptides, long-chain molecules and highly potent APIs, alongside process development, optimization and custom synthesis. Through its discovery and CDMO activities, it offers drug-discovery and development support across APIs, intermediates and formulations.[14][15][16]
In FY2025–26, Global Generics contributed 89% of reported revenue, PSAI 10% and Others 1%; these are business-segment shares, not sales shares for individual products.[17] [17][17][17][7][8][9][10][11][12][13][14][15][16]
Geographic presence
Dr. Reddy’s Laboratories’ principal manufacturing locations include sites in Telangana, Andhra Pradesh and Himachal Pradesh in India, as well as Cuernavaca–Cuautla in Mexico and Mirfield in the UK. Its principal research and development facilities include locations in Telangana and Andhra Pradesh, India, and Cambridge, UK.[18][19]
In FY2026, geographic revenue reported for Global Generics was ₹113,737 million from North America (United States and Canada; 38% of total revenue), ₹55,501 million from Europe (19%), ₹62,186 million from India (21%), ₹34,786 million from Russia (12%), ₹9,074 million from other former Soviet Union countries and Romania (3%), and ₹23,749 million from the Rest of World (8%). PSAI and Others were reported separately, without geographic splits in the cited table.[20]
At March 31, 2026, the company reported 27,527 employees: 24,650 in India, 207 in North America, 462 in Europe and 2,208 in the Rest of World.[21] The filing also identifies the North America CEO’s office in Princeton, New Jersey, and lists subsidiaries, joint ventures and associates incorporated across countries including India, the UK, the US, Germany, Brazil, China, Japan, Mexico, Russia and South Africa.[22][23] [18][19][20][20][20][20][20][20][20][20][20][20][20][20][21][21][21][21][21][22][23]
Business segments
Dr. Reddy’s Laboratories reports Global Generics and Pharmaceutical Services and Active Ingredients (PSAI) as its business segments; its FY2026 filing also presents an “Others” revenue category. In FY2026, Global Generics generated approximately 89% of consolidated revenue (Rs.299,033 million), PSAI approximately 10% (Rs.34,773 million), and Others approximately 1% (Rs.2,127 million). [Segment revenue table; FY2026 filing]
Global Generics focuses on finished-dose generic medicines, including tablets, capsules, injections, liquids and creams. PSAI encompasses active pharmaceutical ingredients and intermediates, as well as pharmaceutical services; these include Aurigene’s discovery, research, development and manufacturing services for pharmaceutical and biotechnology companies. The FY2026 filing is the latest annual filing identified in the available document set; the set also includes filings for FY2022–FY2025. [Business descriptions; FY2026 filing] [17][17][17][17][17][17][17][17][24][25][26][27][28][29][30][31][32][33]
Company history
Dr. Reddy’s Laboratories was founded in 1984 by Dr. Kallam Anji Reddy and two technocrat-entrepreneurs. Its first active pharmaceutical ingredient (API) factory began operating at Bollaram in 1985. The company launched the omeprazole brand Omez in 1991, and opened a branch in Russia in 1992 as it began expanding internationally.[34][35][36]
The company listed American Depositary Shares on the New York Stock Exchange in 2001. In 2002, it established drug-discovery subsidiary Aurigene and entered Europe through the acquisition of BMS Laboratories and its subsidiary Meridian Healthcare in the UK. In 2006, it launched an authorized generic in the United States and passed US$1 billion in revenue.[34][36][7]
Erez Israeli became CEO in 2019. In 2023, Dr. Reddy’s announced an agreement to acquire Mayne Pharma’s U.S. generic prescription-product portfolio.[37][38] [34][35][36][7][37][38]
Sources
- www.drreddys.com[1]
- DR REDDYS LABORATORIES LTD — Full financial report (2026 Y)
- www.drreddys.com[3]
- www.drreddys.com[4]
- www.drreddys.com[7]
- www.drreddys.com[8]
- www.drreddys.com[9]
- www.drreddys.com[10]
- www.drreddys.com[11]
- www.drreddys.com[12]
- apibackend-prod.drreddys.com[13]
- api.drreddys.com[14]
- api.drreddys.com[15]
- api.drreddys.com[16]
- api-events.drreddys.com[35]
- www.drreddys.com[36]
- www.sec.gov[37]
- www.drreddys.com[38]
Continue your research
From company context to financial detail.
Explore original sources and worldwide fundamental financial data and intelligence with Finbar.
Explore DR REDDYS LABORATORIES LTD in Finbar ↗